BON Announces Breakthrough Development of Apple Bio-Electronic Mask: Clinical Data Exceeds Expectations, Targeting $100B+ Medical Aesthetics Market

Bon Natural Life (Nasdaq: BON) announced development of an AI-enabled flexible bio-electronic anti-aging facial mask using apple polyphenols as the core active ingredient.

Rhea-AI Summary

Bon Natural Life (Nasdaq: BON) announced development of an AI-enabled flexible bio-electronic anti-aging facial mask using apple polyphenols as the core active ingredient. The company completed sample development and preliminary internal performance evaluations that exceeded internal benchmarks and plans expanded third-party clinical testing.

The product targets the >$100 billion global anti-aging market and aims for non-invasive, at-home transdermal delivery with optimized large-scale manufacturing to follow.

Argus Feb 19 session

+0.61% close to close Open Argus

Details

News Market Reaction – BON

In the Feb 19 session, BON gained 0.61%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights BON’s expansion into a premium, AI-enabled bio-electronic facial mask u...

Analysis

This announcement highlights BON’s expansion into a premium, AI-enabled bio-electronic facial mask using apple polyphenols, targeting a global anti-aging market exceeding $100 billion. It builds on prior Apple Series initiatives and the company’s AI and bio-manufacturing strategy. Investors may track upcoming third-party clinical testing, progress on large-scale manufacturing, and how this integrates with BON’s weaker 2025 financials, including revenue of $18,670,684 and a net loss of $2,049,431, alongside potential capital-raising under the existing shelf.

Key Figures

Anti-aging market size: $100 billion+ Revenue 2025: $18,670,684 Revenue 2024: $23,844,556 +5 more

Anti-aging market size

$100 billion+

Global anti-aging market referenced for target segment

Revenue 2025

$18,670,684

Year ended Sep 30, 2025 (20-F)

Revenue 2024

$23,844,556

Prior year comparison (20-F)

Revenue 2023

$29,522,353

Two years prior (20-F)

Gross profit 2025

$3,878,821

Year ended Sep 30, 2025 (20-F)

Net loss 2025

$2,049,431

Year ended Sep 30, 2025 (20-F)

Shelf registration size

$500,000,000

Amended F-3 shelf filed Nov 07, 2025

Cash balance

$8,894,053

Cash at Mar 31, 2025 per 6-K

Historical Context

5 past events · Latest: Feb 17

5 events

1. Feb 17

   R&D partnership

   24h Move

   -0.6%

   Joint lab with Chang'an Pilot for AI-optimized bio-manufacturing of natural ingredients.

2. Dec 10

   Product + sales deal

   24h Move

   +8.2%

   Kombucha-inspired product launch plus $12M strategic sales agreement in Greater China.

3. Nov 25

   Cooperation agreement

   24h Move

   +0.6%

   36‑month non-exclusive China agreement with $26M guaranteed sales for tea pigment products.

4. Sep 09

   Apple products deal

   24h Move

   +24.7%

   $18M cooperation for second‑generation Apple Series metabolic health products in Greater China.

5. Sep 02

   AI drug discovery

   24h Move

   +5.0%

   AI-powered platform identified tea polyphenols with promising weight-management potential in early studies.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

apple polyphenols, proanthocyanidins, quercetin, transdermal delivery, +4 more

8 terms

apple polyphenols medical

"Serving as the core natural active ingredient of this product, apple polyphenols are extracted..."

Apple polyphenols are natural chemical compounds extracted from apples and apple skins that act like plant-made protectors, similar to how a sunscreen guards skin from damage. Investors care because these extracts are used as ingredients in foods, supplements and cosmetics for claimed health benefits and as natural preservatives; demand, regulatory approval, and scientific evidence can directly affect product sales, margins and a company’s market potential.

proanthocyanidins medical

"contain polyphenolic compounds such as proanthocyanidins and quercetin."

Proanthocyanidins are natural compounds found in many plants—such as berries, grapes and pine bark—that act like antioxidants and can help protect cells from damage. Investors care because these ingredients are common in dietary supplements, foods and some therapeutics; evidence about their health benefits, safety or regulatory status can affect product demand, labeling claims and the financial outlook for companies that sell or develop them.

quercetin medical

"contain polyphenolic compounds such as proanthocyanidins and quercetin."

A plant compound found in many fruits, vegetables and teas, quercetin is commonly sold as a dietary supplement and studied for antioxidant and anti-inflammatory effects. Investors monitor quercetin because clinical trial results, regulatory rulings, patent activity, or supply changes can affect companies that sell supplements or develop related medicines — like watching a key ingredient whose safety, effectiveness or availability can change a product’s market value.

transdermal delivery medical

"Leveraging advanced transdermal delivery systems, this product integrates plant-derived..."

Transdermal delivery is a way to get a medicine into the body through the skin, typically using patches, gels or creams that release the drug steadily into the bloodstream. For investors it matters because this route can improve patient convenience and adherence, enable steady dosing, reduce side effects, and create distinct product features and patents that affect market size, pricing power, and regulatory approval complexity.

flexible bio-electronic technical

"integrated with AI-enabled flexible bio-electronic technology."

Flexible bio-electronic describes soft, bendable electronic devices designed to interact with the body’s tissues or fluids—think of electronics built into a bandage or a thin patch that can bend and stretch with skin or organs. They matter to investors because they enable new kinds of medical sensors, diagnostics and treatments that are more comfortable, longer-lasting and can reach areas rigid devices cannot, potentially opening large markets and recurring revenue but also carrying clinical and regulatory development risk.

photoprotective medical

"for their antioxidant, anti-inflammatory, and photoprotective properties."

Photoprotective describes products, ingredients or treatments designed to protect skin, materials or surfaces from harmful effects of sunlight, especially ultraviolet (UV) radiation. For investors this matters because photoprotective properties drive product demand, affect regulatory approval and labeling, influence patent value and liability risk, and can differentiate brands in markets like sunscreens, textiles and coatings—similar to how rustproofing adds long-term value to a car.

melanin metabolism medical

"support melanin metabolism, contributing to visible improvements in skin firmness..."

Melanin metabolism is the biological process by which the body produces, modifies, and breaks down melanin, the pigment that gives skin, hair, and eyes their color. For investors, changes or disruptions in this process underpin products and treatments—such as cosmetics, dermatology drugs, and therapies for pigment disorders—and can drive regulatory reviews, patent value, market demand, and clinical trial outcomes, much like supply-chain changes affect a factory’s output.

clinical testing medical

"the Company plans to initiate expanded third-party clinical testing while advancing..."

Clinical testing is the stepwise process of studying a drug, vaccine or medical device in human volunteers to show whether it is safe and works as intended. Like road‑testing a new car before it goes on sale, clinical testing produces data that regulators use to approve products and that investors use to judge a therapy’s commercial chances, timelines and financial risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

XI'AN, China, Feb. 19, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("Bon" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, today announced the successful development of a premium anti-aging facial mask incorporating apple polyphenols as its core active ingredient and integrated with AI-enabled flexible bio-electronic technology. Leveraging advanced transdermal delivery systems, this product integrates plant-derived active ingredients with intelligent flexible electronics, creating a next-generation skin care solution designed to be non-invasive, painless, and suitable for at-home use.

Serving as the core natural active ingredient of this product, apple polyphenols are extracted from premium apple pomace and contain polyphenolic compounds such as proanthocyanidins and quercetin. These compounds are widely studied for their antioxidant, anti-inflammatory, and photoprotective properties. Published research indicates that apple polyphenols may help inhibit collagen degradation, reduce UV-induced oxidative stress, and support melanin metabolism, contributing to visible improvements in skin firmness, brightness, and overall appearance. Powered by its AI-enabled flexible bio-electronic platform, BON's mask combines flexible electronic materials with smart controlled-release technology to enhance transdermal penetration of the active ingredients. This approach is designed to address the absorption limitations typically associated with conventional topical skincare products.

At present, the Company has completed sample development and preliminary internal performance evaluations of the AI-powered flexible bio-electronic mask incorporating apple polyphenols. Across key performance indicators — including the appearance of fine lines, skin firmness, UV-related skin stress, and overall brightness — the initial results have exceeded internal benchmarks. In the next phase, the Company plans to initiate expanded third-party clinical testing while advancing product finalization and optimizing large-scale manufacturing processes.

According to industry data, the global anti-aging market has surpassed $100 billion, with premium transdermal delivery devices and advanced formulations representing one of the fastest-growing segments. By combining the functional properties of apple polyphenols with proprietary bio-electronic mask technology, BON believes it is well positioned to capture a first-mover advantage within this emerging premium segment.

Hu Yongwei, Chairman and CEO of BON, stated: "This is a strategic product driven by technology and guided by market demand. Through AI-powered flexible electronic technology, we are enhancing the transdermal delivery efficiency of apple polyphenols, addressing growing consumer demand for high-performance, non-invasive anti-aging solutions. This milestone represents BON's entry into the high-growth, high-value medical-grade beauty segment and reinforces our ecosystem strategy of 'AI + Bioactive Ingredient.' By delivering safe and effective skincare innovations, we aim to establish a second growth engine characterized by strong pricing power, high repurchase potential, and attractive margins, creating long-term value for our shareholders''.

About Bon Natural Life Limited ("BON")

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

 

View original content:https://www.prnewswire.com/news-releases/bon-announces-breakthrough-development-of-apple-bio-electronic-mask-clinical-data-exceeds-expectations-targeting-100b-medical-aesthetics-market-302692177.html

SOURCE Bon Natural Life Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BON announce on February 19, 2026 about its apple bio-electronic mask?

BON announced successful sample development and preliminary internal performance evaluations exceeding internal benchmarks. According to the company, the AI-enabled flexible bio-electronic mask combines apple polyphenols with smart controlled-release to enhance transdermal delivery and plans expanded third-party clinical testing.

How does BON say the apple polyphenols work in the BON mask (BON)?

Apple polyphenols serve as the core active and are claimed to support antioxidant and anti-inflammatory effects. According to the company, extracted polyphenols like proanthocyanidins and quercetin aim to help firmness, brightness, and reduce UV-related stress.

What are BON's next steps and timeline for clinical testing and manufacturing for the new mask?

BON plans expanded third-party clinical testing and continued product finalization before scaling manufacturing. According to the company, the next phase focuses on external clinical validation and optimizing large-scale production processes for commercialization readiness.

What market opportunity did BON cite for its bio-electronic apple mask (BON)?

BON cited the global anti-aging market exceeding $100 billion and identified premium transdermal devices as a fast-growing segment. According to the company, combining proprietary bio-electronics with apple polyphenols targets a premium, medical-grade beauty niche and potential first-mover advantage.

Will the BON bio-electronic mask be for at-home or clinical use according to BON?

BON describes the mask as a non-invasive, painless solution designed for at-home use. According to the company, AI-enabled flexible electronics and controlled-release technology are intended to improve user convenience and transdermal absorption outside clinical settings.